

# Target patient populations

2023

 **NOVARTIS**




# Cardiovascular, renal & metabolic




# Heart failure

## Prevalence

Thousand patients



### Reduced ejection fraction



### Preserved ejection fraction

HFrEF treated population includes patients on ACE inhibitors, ARBs, ARNI, beta blockers, MRA, SGLT2s. DRG, NHANES, Novartis. Epidemiology numbers include patients without access.

HFpEF treatment mainly for co-morbidities.

Numbers rounded.


Data for year 2023.

Sources: Cardio Vascular Resource Group,

# Atherosclerotic cardiovascular disease

## Prevalence

Thousand patients




LLT – Lipid lowering therapy. Lp(a) – Lipoprotein(a). Diagnosed covers patients with established ASCVD. Treated with statin and/or ezetimibe. Advanced LLT include PCSK9i mAbs, Leqvio, Bempedoic acid. Lp(a) goals based on lower of local guidelines and real-world evidence. Guidelines: Elevated Lp(a) if  $\geq 70$  mg/dl, in JP/ES  $\geq 90$  mg/dl. Real-world data: China/Japan  $\geq 30$  mg/dl. Numbers rounded. Data for year 2023. Sources: Clarivate/ DRG, AHA, ACC, Adelphi/ JAMA, IQVIA, INSEE, Novartis. Epidemiology numbers include patients without access.

# IgA nephropathy

## Prevalence


Thousand patients



Persistent proteinuria >1g and GFR >30 ml. Treated includes ACEi, ARBs, SGLT2i, corticosteroids, non-steroidal immunosuppressants, anti-CD20s, anti-c5s, anti-platelet agents, diuretics, statins, NSAIDs, alternative medicine. Numbers rounded. Data for year 2024. Sources: CDA, Clarivate, Opti-Brand PMR, Adelphi, Novartis. Epidemiology numbers include patients without access.

# Complement 3 glomerulopathy


## Prevalence



Persistent proteinuria >1g and GFR >30 ml. Treated includes ACEi/ARBs, SGLT2i, corticosteroids, non-steroidal immunosuppressants, anit-CD20, anti-c5s, alternative medicine. Numbers rounded. Data for year 2024. Sources: CDA, Clarivate, UN, Adelphi, Opti-Brand PMR, OBRx, Novartis. Epidemiology numbers include patients without access.

# Paroxysmal nocturnal hemoglobinuria

## Prevalence



Treated with complement therapy. Numbers rounded. Data for year 2023. Sources: DRG, Evaluate, Novartis. Epidemiology numbers include patients without access.

# Immunology

 NOVARTIS






# Psoriasis

## Prevalence

Thousand patients




Moderate-severe defined as PASI > 10 or BSA > 10 AND DLQI > 10; For China M-S BSA>3. Systemic treated includes orals (incl. retinoids, immunosuppressants, PDE4s, TYK2s, JAKs) and biologics but excludes topicals. Numbers rounded. Data for year 2023. Source: DRG, IQVIA, Novartis. Epidemiology numbers include patients without access.

# Psoriatic arthritis

## Prevalence

Thousand patients




Systemic treated includes DMARDs, orals and biologics. Numbers rounded. Data for year 2023. Source: DRG, IQVIA, APLD, Novartis. Epidemiology numbers include patients without access.

# Axial spondyloarthritis

## Prevalence

Thousand patients




Systemic treated includes DMARDs, orals and biologics. China numbers do not include nr-axSpA. Numbers rounded. Data for year 2023. Source: DRG, IQVIA, Novartis. Epidemiology numbers include patients without access.

# Hidradenitis suppurativa

## Prevalence

Thousand patients




Numbers rounded. Moderate to severe corresponds to Hurley State II and III. Treated with topicals, antibiotics, anti-androgens, DMARDs biologics and surgery. Data for year 2023. Source: IQVIA, DRG, Novartis. Epidemiology numbers include patients without access.

# Chronic spontaneous urticaria

## Prevalence

Thousand patients



Treated refers to adults with antihistamines and biologics. Epidemiology numbers include patients without access.

Uncontrolled despite treatment with H1, H2 antihistamines incl. dose escalation.

Numbers rounded.

Data for year 2023.

Source: GA2LEN, World Bank, Novartis.


# Neuroscience



# Multiple sclerosis

## Prevalence

Thousand patients




DMT – Disease modifying therapy. RMS – Relapsing multiple sclerosis. RMS includes clinically isolated syndrome, relapsing-remitting and active secondary progressive forms of multiple sclerosis. Numbers rounded. Data for year 2023. Sources: MSIF, IQVIA, Stethos, DRG, Novartis. Epidemiology numbers include patients without access.

# Spinal muscular atrophy



## Incidence

Patients



## Prevalence

Patients



GTx – Gene therapy. Numbers rounded. Data for year 2023. Eligible excludes share with elevated anti-AAV9 antibody titers. Source: CDC, CureSMA, NIH, Novartis. Epidemiology numbers include patients without access.




# Oncology



# HR+/HER2- breast cancer

## Incidence

Thousand patients





Treated with systemic therapy. Numbers rounded. Data for year 2023. Sources: Kantar, DRG, Novartis. Epidemiology numbers include patients without access.

# Prostate cancer

## Incidence

Thousand patients




Numbers rounded. Data for year 2023. Sources: Kantar, Novartis, China National Office for Cancer Prevention and Control. Epidemiology numbers include patients without access.

# Chronic myeloid leukemia

## Prevalence

Thousand patients



Prevalence includes all Ph+ CML incl. acute phase. Treated with 1st and 2nd generation TKIs. Numbers rounded. Data for year 2023. Sources: Kantar, Novartis. Epidemiology numbers include patients without access.

**Thank you**

 **NOVARTIS**

